Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis

Bone Marrow Transplantation volume 47, pages 196–202 (2012)Cite this article

Abstract

We conducted a retrospective study to evaluate the outcome of 94 consecutive patients with high-risk hematological malignancies who received allo-PBSCT, following idarubicin (IDA)-intensified BUCY2 (IDA-BUCY2) myeloablative conditioning regimens (n=53) and BUCY2 conditioning regimens (n=41). IDA 15 mg/m2 once daily was administered by continuous infusion on days −11 to −9, followed by BU, 3.2 mg/kg in divided doses daily, on days −6 to −4, and i.v. injection of CY, 1.8 g/m2 once daily on days −3 to −2 in the IDA-BUCY2 group. The relapse rate in patients in the IDA-BUCY2 and BUCY2-conditioning regimens group was 18.9 and 39%, respectively (P=0.030). There was no significant difference in terms of TRM. The cumulative probabilities of OS and disease-free survival at 2 years for patients conditioned with the IDA-BUCY2 and BUCY2 regimens were 65.3% vs 46.8% (P=0.038), and 63.5% vs 43.4% (P=0.025), respectively. Multivariate analysis showed that IDA-BUCY2 regimens and limited chronic GVHD were the only two factors resulting in improved survival and reduced relapse rate. This retrospective study suggests that IDA-intensified BUCY2 may be substituted for BUCY2 as conditioning regimen for patients with high-risk hematological malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Malignedell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  2. Appelbaum FR . Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385–389.

    Article  CAS  PubMed  Google Scholar 

  3. Lee KH, Lee JH, Choi SJ, Lee JH, Kim S, Seol M et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003; 32: 835–842.

    Article  CAS  PubMed  Google Scholar 

  4. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312.

    Article  CAS  PubMed  Google Scholar 

  5. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577–584.

    Article  PubMed  Google Scholar 

  6. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233–241.

    Article  CAS  PubMed  Google Scholar 

  7. Aschan J . Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol 2007; 20: 295–310.

    Article  CAS  PubMed  Google Scholar 

  8. Mengarelli A, Iori AP, Guglielmi C, Romano A, Cerretti R, Torromeo C et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002; 87: 52–58.

    CAS  PubMed  Google Scholar 

  9. Toubai T, Tanaka J, Mori A, Hashino S, Kobayashi S, Ota S et al. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies. Clin Transplant 2004; 18: 552–557.

    Article  PubMed  Google Scholar 

  10. Mengarelli A, Iori AP, Guglielmi C, Perrone MP, Gozzer M et al. Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia 2000; 14: 2052–2058.

    Article  CAS  PubMed  Google Scholar 

  11. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2008; 14: 568–575.

    Article  CAS  PubMed  Google Scholar 

  12. Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Graf T et al. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant 2009; 44: 785–792.

    Article  CAS  PubMed  Google Scholar 

  13. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27: 5397–5403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM . Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res 1990; 50: 6525–6528.

    CAS  PubMed  Google Scholar 

  15. Case DC, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS et al. Phase II study of intravenous idarubicin in unfavourable non-Hodgkin's lymphoma. Leuk Lymphoma 1993; 10: 73–79.

    Article  PubMed  Google Scholar 

  16. Ferrara F, Palmieri S, Annunziata M, Viola A, Pocali B, Califano C et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573–576.

    Article  CAS  PubMed  Google Scholar 

  17. Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234–241.

    Article  CAS  PubMed  Google Scholar 

  18. Ferrara F, Palmieri S, Pedata M, Viola A, Izzo T, Criscuolo C et al. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol Oncol 2009; 27: 40–45.

    Article  CAS  PubMed  Google Scholar 

  19. Ferrara F, Mele G, Palmieri S, Pedata M, Copia C, Riccardi C et al. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematol Oncol 2009; 27: 198–202.

    Article  CAS  PubMed  Google Scholar 

  20. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT : a GOEL-AMS trial. Blood 2004; 104: 3028–3037.

    Article  CAS  PubMed  Google Scholar 

  21. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction chemotherapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia:data from the German AML cooperative group (AMLCG) 1992 trial. Blood 2003; 101: 64–70.

    Article  CAS  PubMed  Google Scholar 

  22. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML:Analysis of 1,612 patients entered into the MRCAML10 trial—The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  23. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a South west Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  24. Schoch C, Haferlach T, Haase D, Fonatsch C, Löffler H, Schlegelberger B et al. Patients with denovo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112: 118–126.

    Article  CAS  PubMed  Google Scholar 

  25. Appelbaum FR . Who should be transplanted for AML. Leukemia 2001; 15: 680–682.

    Article  CAS  PubMed  Google Scholar 

  26. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T . Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1092 patients with de novo AML. Leukemia 2004; 18: 120–125.

    Article  CAS  PubMed  Google Scholar 

  27. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndrome: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408.

    CAS  PubMed  Google Scholar 

  28. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  29. Thiede C, Florek M, Bornhäuser M, Ritter M, Mohr B, Brendel C et al. Rapid quantication of mixed chimerism using multiplex amplification of short tandem repeat markers and uorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.

    Article  CAS  PubMed  Google Scholar 

  30. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/hapl oidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  PubMed  Google Scholar 

  31. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  32. Sullivan KM . Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. Blackwell Scientific: London, Oxford, 1999, pp 515–536.

    Google Scholar 

  33. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  34. Kaplan EL, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  35. Cox DR . Regression models and life-tables. JR Stat Soc 1972; 34: 187–189.

    Google Scholar 

  36. Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234–241.

    Article  CAS  PubMed  Google Scholar 

  37. Ferrara F, Annunziata M, Schiavone EM, Copia C, De Simone M, Pollio F et al. High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study. Hematol J 2001; 2: 214–219.

    Article  CAS  PubMed  Google Scholar 

  38. Jerjis S, Roovers E, Muus P, Schaap N, De Witte T . Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone Marrow Transplant 1998; 22: 13–19.

    Article  CAS  PubMed  Google Scholar 

  39. Brown RA, Wolff SN, Fay JW, Pineiro L, Collins Jr RH, Lynch JP et al. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group. Leuk Lymphoma 1996; 22: 271–277.

    Article  CAS  PubMed  Google Scholar 

  40. Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant 2005; 35: 549–556.

    Article  CAS  PubMed  Google Scholar 

  41. Mohty M, Labopin M, Volin L, Gratwohl A, Socié G, Esteve J et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 303–306.

    Article  PubMed  Google Scholar 

  42. Stein AS, Palmer JM, O’Donnell MR, Kogut NM, Spielberger RT, Slovak ML et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009; 15: 1407–1414.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Aschan J . Allogeneic haematopoietic stem cell transplantation: current status and future outlook. Br Med Bull 2006; 77–78: 23–36.

    Article  PubMed  Google Scholar 

  44. Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1083–1094.

    Article  PubMed  Google Scholar 

  45. Lake RA, Robinson BW . Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 2005; 5: 397–405.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. M Hong and Q Wu: These authors contributed equally to this work

Authors and Affiliations

  1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China

    M Hong, Q Wu, C Hu, J Fang, Y You, Z Zhong, P Zou, Y Hu & L Xia

Authors
  1. M Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Q Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y You
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Xia.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hong, M., Wu, Q., Hu, C. et al. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone Marrow Transplant 47, 196–202 (2012). https://doi.org/10.1038/bmt.2011.66

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.66

Keywords

This article is cited by

Search

Advanced search

Quick links